Neurocrine公司抑郁症新药II期研究未达主要终点

GPLP犀牛财经2025-11-19

近日，神经科学领域的生物制药公司Neurocrine Biosciences宣布，在研抑郁症药物NBI-1070770的II期临床试验未能达到预设主要终点，这一结果也为其与武田制药的合作研发项目再添波折。据公开信息显示，NBI-1070770是一种选择性口服NMDA受体负变构调节剂，主要开发用于对至少一种抗抑郁药反应不足的成人重度抑郁症（MDD）患者，通过调节大脑关键蛋白发挥作用。该药物的研发权益...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2584786920?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-19 19:34","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2584786920","market":"us","top_or_hot":-1,"title":"Neurocrine公司抑郁症新药II期研究未达主要终点","media":"GPLP犀牛财经","content":"<div>\n<p>近日，神经科学领域的生物制药公司Neurocrine Biosciences宣布，在研抑郁症药物NBI-1070770的II期临床试验未能达到预设主要终点，这一结果也为其与武田制药的合作研发项目再添波折。据公开信息显示，NBI-1070770是一种选择性口服NMDA受体负变构调节剂，主要开发用于对至少一种抗抑郁药反应不足的成人重度抑郁症（MDD）患者，通过调节大脑关键蛋白发挥作用。该药物的研发权益...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119193517950e580f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurocrine公司抑郁症新药II期研究未达主要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurocrine公司抑郁症新药II期研究未达主要终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-19 19:34 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119193517950e580f&s=b><strong>GPLP犀牛财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，神经科学领域的生物制药公司Neurocrine Biosciences宣布，在研抑郁症药物NBI-1070770的II期临床试验未能达到预设主要终点，这一结果也为其与武田制药的合作研发项目再添波折。据公开信息显示，NBI-1070770是一种选择性口服NMDA受体负变构调节剂，主要开发用于对至少一种抗抑郁药反应不足的成人重度抑郁症（MDD）患者，通过调节大脑关键蛋白发挥作用。该药物的研发权益...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119193517950e580f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119193517950e580f&s=b","article_id":"2584786920","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119193517950e580f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2584786920","pubTimestamp":1763552095,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，神经科学领域的生物制药公司Neurocrine Biosciences宣布，在研抑郁症药物NBI-1070770的II期临床试验未能达到预设主要终点，这一结果也为其与武田制药的合作研发项目再添波折。该药物的研发权益源于2020年Neurocrine与武田的合作，当时武田授予其七个在研药物的独家许可，NBI-1070770便是其中针对抑郁症的核心资产之一。Neurocrine在声明中指出，NBI-1070770整体耐受性良好，试验期间未报告严重不良事件，但所有剂量组均未在主要终点上展现出优于安慰剂的统计学差异。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","TAK":"武田制药"},"translate_title":"Phase II study of Neurocrine's new drug for depression failed to meet primary endpoint","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":0.9},"content_text":"近日，神经科学领域的生物制药公司Neurocrine Biosciences宣布，在研抑郁症药物NBI-1070770的II期临床试验未能达到预设主要终点，这一结果也为其与武田制药的合作研发项目再添波折。据公开信息显示，NBI-1070770是一种选择性口服NMDA受体负变构调节剂，主要开发用于对至少一种抗抑郁药反应不足的成人重度抑郁症（MDD）患者，通过调节大脑关键蛋白发挥作用。该药物的研发权益源于2020年Neurocrine与武田的合作，当时武田授予其七个在研药物的独家许可，NBI-1070770便是其中针对抑郁症的核心资产之一。本次II期临床试验于去年3月启动，为随机、多中心、双盲安慰剂对照研究，共招募73名符合条件的MDD患者，按1:1:1:3的比例分配至三种不同剂量的NBI-1070770组与安慰剂组，治疗周期为四周。试验主要终点设定为用药第5天，通过蒙哥马利-奥斯伯格抑郁评定量表（MADRS）评估患者抑郁严重程度较基线的变化。Neurocrine在声明中指出，NBI-1070770整体耐受性良好，试验期间未报告严重不良事件，但所有剂量组均未在主要终点上展现出优于安慰剂的统计学差异。首席医疗官Sanjay Keswani表示：“我们对这一结果感到失望，但数据中仍有值得进一步研究的方面，团队将持续分析以确定后续方向。”虽然NBI-1070770的II期研究未达主要终点，但Neurocrine在抑郁症领域仍有其他研发项目。2025年9月，其公布了另一款抑郁症药物osavampator的积极II期数据，并已于2025年1月启动了该药物的III期临床项。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584786920","isCrawlerRequest":true}